The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2019
Filed:
May. 22, 2017
Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
Applicant:
Nestec S.a., Vevey, CH;
Inventors:
Sharat Singh, San Diego, CA (US);
Anjali Jain, San Diego, CA (US);
Venkateswarlu Kondragunta, San Diego, CA (US);
Assignee:
NESTEC S.A., Vevey, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01); G01N 33/15 (2006.01); G01N 33/48 (2006.01);
U.S. Cl.
CPC ...
G01N 33/564 (2013.01); G01N 33/15 (2013.01); G01N 33/48 (2013.01); G01N 33/68 (2013.01); G01N 2333/70546 (2013.01); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01);
Abstract
The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-α4β7 integrin drug.